Cytotoxic T lymphocytes (CTL) are important to the control of viral replication and their presence may be important to disease outcome. An understanding of the spectrum of proteins recognized by hepatitis C virus (HCV)-specific CTL and the functional properties of these cells is an important step in understanding the disease process and the mechanisms of persistent infection, which occurs in the majority of HCV-infected individuals. In this report we identify HCV-specific CTL responses restricted by the HLA class I molecules A2, A3, All, A23, B7, B8, and B53. The epitopes recognized by these intrahepatic CTL conform to published motifs for binding to HLA class I molecules, although in some cases we have identified CTL epitopes for which no published motif exists. The use of vectors expressing two different strains of HCV, HCV-1 and HCV-H, revealed both strain-specific and cross-reactive CTL. These HCV-specific CTL were shown to produce cytokines including IFN-y, TNF-a, GM-CSF, IL-8, and IL-10 in an antigen-and HLA class I-specific manner. These studies indicate that the CTL response to HCV is broadly directed and that as many as five different epitopes may be targeted in a single individual. The identification of minimal epitopes may facilitate peptide-specific immunization strategies. In addition, the release of proinflammatory cytokines by these cells may contribute to the pathogenesis of HCV-induced liver damage. (J. Clin. Invest. 1995. 96:2311-2321
Introduction
Infection with hepatitis C virus (HCV)' leads to chronic liver disease in 50-70% of infected individuals (1) . In chronically infected individuals, there is persistent viremia and liver damage despite the presence of both humoral (2, 3) and cellular immune responses (4) (5) (6) (7) . The mechanism of persistent infection despite such vigorous immune responses is unknown. In hepatitis B virus (HBV) infection, cytotoxic T lymphocytes (CTL) are present in the acute phase of hepatitis (8, 9) but their role in inhibition of viral replication is unknown. In the chronic hepatitis, the presence of virus-specific CTL is thought to lead to tissue destruction in the absence of control of viral replication (10) .
Previously this laboratory has reported HLA class I-restricted CTL specific for the core, El, E2, and NS2 proteins among liver-infiltrating lymphocytes of persons with chronic HCV, establishing the existence of a CTL response to this virus in chronically infected humans (4, 5) . In this report, we extend the findings regarding cellular immunity to HCV by demonstrating that multiple proteins may serve as targets for HCV-specific CTL within the context of the immune response in an individual. Using vaccinia-HCV recombinant viruses which express two different strains of HCV, we have also identified CTL which recognize only one strain of HCV, a finding which may have important implications for vaccine development.
Despite the broadly directed CTL response, CTL would be capable of killing only a minority of hepatocytes, since in most cases only a fraction of hepatocytes are infected with HCV (11) . Recent studies in a transgenic mouse model of fulminant HBV infection have shown that production of IFN-y and TNF-a by virus-specific CTL may amplify the ability of the CTL to lyse infected cells (12) . Production of IFN-y and TNF-a by murine HBV-specific CTL leads to the recruitment of large numbers of inflammatory cells, and also serves to inhibit viral replication (13) . The production of cytokines, based on patterns of cytokine release and functional studies, by murine CD4 lymphocyte populations has been well characterized (reviewed in reference 14) . The cytokines released by human CD8+ CTL have been less well characterized, and may be important to our understanding of the balance between the tissue destruction initiated by virusspecific CTL and their role in controlling viral replication (15) . Previously this laboratory has reported the production of IFN- y, TNF-a, and TNF-f3 by HIV-l-specific CTL (16) . In this report we extend these findings to show that HCV-specific CTL produce additional cytokines, including GM-CSF, IL-8, and, in some cases, IL-10 upon recognition of target cells.
Methods
Subjects. HCV-seropositive subjects with evidence of chronic liver disease (at least fourfold elevations in serum transaminases for at least 6 mo) underwent liver biopsy by modified Klatskin technique before a-IFN therapy. All subjects were HBV and HIV-1 seronegative, and had evidence of mild to moderate chronic active hepatitis on histologic examination of liver tissue. All subjects gave informed consent, and the Hepatitis C Virus-specific CTL: Epitopes and Cytokine Production Cell lines. EBV-transformed B-lymphoblastoid cell lines (B-LCL) were established and maintained as described previously (17) in RPMI 1640 media (Sigma Chemical Co., St. Louis, MO) supplemented with 2 mM L-glutamine, 50 U/ml of penicillin, 50 pg/ml of streptomycin, and 10 mM Hepes, in addition to 20% heat-inactivated FCS (R-20 medium). Additional B-LCL were obtained from the American Society for Histocompatibility and Immunogenetics B cell line repository.
HLA typing. HLA typing of subjects was performed on fresh PBMC by the Massachusetts General Hospital Tissue Typing Laboratory, using standard serologic techniques.
Vaccinia virus constructs. Vaccinia-HCV recombinant viruses were constructed to express the structural and nonstructural proteins of the HCV (see Fig. 1 (20) . After the screening of 93I, vv-NS4, which expresses Gly,590-Lys2050 of HCV-1, and vv-NS5A and NS5B, which express Gly2005-Gly2396 and Gly2396-Arg3011 of HCV-1, respectively, became available (20, 22) . A vv expressing only the Escherichia coli 6-galactosidase gene (vv-Lac) was used as a control (21) . All vaccinia-HCV recombinant viruses were demonstrated to express the appropriate HCV proteins by radioimmunoprecipitation (18, 20 , and unpublished data).
Synthetic peptides. Synthetic peptides corresponding to the aa sequences of the HCV-1 strain of Choo et al. (23) were synthesized as free acids by Cambridge Research Biochemicals (Cambridge, MA) using the Fmoc method (24) . Peptide 1 corresponds to aa 1-20, and adjacent serial peptides overlap by 10 aa. For aa 906-1619, the overlapping peptides were 13 aa in length and overlapped by 10 aa. Synthetic peptides spanning the NS5B region were synthesized based on the amphipathic profile of residues spanning this region (reference 25, kindly provided by Dr. Jay Berzofsky, NIAID). Fine mapping was achieved using additional smaller peptides in free acid form which were purchased commercially (IDEC Pharmaceuticals, La Jolla, CA) or synthesized on an automated peptide synthesizer (model 482A, Applied Biosystems, Inc. Foster City, CA). All peptides were reconstituted in sterile distilled water containing 10% DMSO (Sigma Chemical Co.) and 1 mM dithiothreitol (Sigma Chemical Co.).
Cloning of liver-infiltrating lymphocytes. CD8+ liver-infiltrating lymphocytes were expanded from the liver biopsy specimens as described (4, 5) , using the bispecific monoclonal antibody CD3,4B (reference 26, kindly supplied by Dr. Johnson Wong, Massachusetts General Hospital, Boston, MA). 1 x 106 of the expanded cells were restimulated with 4 ml of feeder cell suspension, which consisted of 106 cells/ml of irradiated (30 Gy) allogeneic PBMC in R-10 media supplemented with 100 U/ml of recombinant IL-2 (rIL-2), and were tested for HCV-specific cytolytic activity on day 10. If screening of these expanded CD8+ lymphocytes showed HCV-specific cytolytic activity (arbitrarily defined as > 20% specific lysis), cells were cloned at limiting dilution as described (5). Developing cells were selected from 96-well plates in which < 33% of the cells displayed visible growth. These cells were restimulated with irradiated feeder cells and the anti-CD3 monoclonal antibody 12F6 as described (17) , and then tested for HCV-specific cytolytic activity. No cells were detected with specificity for more than one HCV protein, and maintained specificity over prolonged periods of in vitro culture in the absence of specific antigenic stimulation, the cells are operationally are referred to as lines (5, 17) .
Cytotoxicity assay using vaccinia-infected target cells. B-LCL were infected with either recombinant vaccinia-HCV vectors or a control vaccinia virus at a multiplicity of infection of 5-10 plaque-forming units (pfu)/cell, incubated overnight at 370C in 5% CO2, labeled with Na2(5"CrO4) and used as target cells (5 x 103 cells/well) in a chromium release assay (27) . Supernatants were harvested at 4 h, and percent specific cytotoxicity was determined by the formula [(release in assay -spontaneous release)/(maximum release -spontaneous release)] x 100. Assays were excluded from analysis if the spontaneous release value was > 30%. Results are reported as the mean of triplicate values, with a standard deviation of < 5%.
Cytotoxicity assay using synthetic peptide-sensitized target cells. B-LCL were pelleted and resuspended in fresh R-20 and labeled overnight with 5"Cr. Cells (1 x 106) were then resuspended in 0.2 ml of R-10 and peptide was added; after a 1-h incubation at 37°C, cells were washed three times and used as targets in the cytotoxicity assay. The concentration of peptides for screening ranged from 100-300 jsg/ml unless otherwise indicated. For screening of large numbers of peptides in some assays, B-LCL were simultaneously sensitized with two noncontiguous peptides, a method which gave equivalent results to screening with individual peptides (data not shown).
For fine mapping experiments, results are shown using the lines that grew best in long term culture. For these experiments, B-LCL were labeled with 5"Cr, washed three times, and then incubated with the indicated concentration of peptide in a 96-well plate. After a 1-h incubation, effector cells were added to the wells, and the supernatant was harvested at 4 h. Cytokine release assay. Effector cells were incubated with 105 peptide-sensitized target cells per well in 96-well U-bottom plates in a total volume of 200 ,ul of R-10 medium for 24 h at 37°C in a 5% CO2 chamber. Previous studies (16) had demonstrated that peak cytokine release was at 24 h, when measured at 4, 6, 24, and 48 h. Since B-LCL may constitutively produce cytokines (16) , target cells were irradiated with 100 Gy before incubation with the effector cells. No difference was detected in measurement of cytokines performed with irradiated and nonirradiated target cells (reference 16, and data not shown). Additional controls consisted of effector cells alone cultured in the presence of 5 ,ug/ml of concanavalin A (conA) and target cells incubated with peptide alone for 24 h and then lysed with 1% Triton X-100 before measurement of cytokine release. Lines were tested for cytokine release at an E/T of 1:1. Supernatant fluid was harvested and stored at -70°C until testing for specific cytokine release. Commercially available enzyme-linked immunoabsorbent assays were performed according to manufacturer's instructions. ELISA assays were obtained commercially from Endogen (TNF-a, IL-10, GM-CSF, IFN-y; Boston, MA); Bender MedSystems (1L-8; Vienna, Austria); and Innogenetics (IL-4 and 11-6; Antwerp, Belgium). Chromium release assays were performed in parallel with all cytokine release assays to serve as a control for virus specific killing. We were unable to detect HCV-specific cytolytic activity within expanded CD8+ liver-infiltrating lymphocytes in another 12 subjects studied during this time period; and 2 additional subjects had HCV-specific activity within expanded CD8+ liver-infiltrating lymphocytes, but we were unable to isolate HCV-specific CTL lines which grew well enough in long term culture sufficient to perform multiple assays or identify the precise epitope recognized by these cells. Thus 6 out of 15 subjects studied during this time period had evidence of HCVspecific CTL that recognized either HCV-1 or the H strain within the CD8+ liver-infiltrating lymphocytes. Recombinant vaccinia virus expressing the nonstructural proteins were only available for the latter half of the study. All HCV-specific lines were confirmed to be CD8+ by FACS® analysis (data not shown).
HCV-specific CTL are restricted by HLA class I molecules. CD8+ CTL recognize virally infected cells through interaction of the T cell receptor with a trimolecular complex consisting of a viral peptide fragment, MHC class I molecule, and beta 2 microglobulin (28) . To HCV-specific CTL recognize 8-10 aa epitopes in structural and nonstructural proteins. Peptide fragments presented to class I-restricted CTL are typically 8-10 aa in length (29) . Incubating target cells with synthetic peptide has been shown to bypass the normal requirements for endogenous processing of viral peptide into fragments of the appropriate length (29) , and thus enables definition of the epitopes recognized by virus-specific CTL. Overlapping 13-20 aa synthetic peptides spanning the appropriate viral proteins were used to map the regions containing epitopes recognized by the HCV-specific CTL. Once a region was identified, amino and carboxy terminal truncations of the peptide containing this region were synthesized and used to sensitize target cells for lysis. These results are shown in Figs. 3-8. As shown in Fig. 3 , the HLA B53-restricted CTL 92T-32 recognized target cells infected with vv-E2/NS2/NS3 and uninfected target cells incubated with a synthetic peptide corresponding to aa 451-470, but not aa 441-460 or aa 461-480. None of the other 54 peptides which spanned the proteins of interest sensitized target cells for lysis (data not shown). Further studies utilizing amino and carboxy terminal truncations of this region showed that the epitope was in the 10 aa sequence RPL-TDFDQGW (aa 460-9), which is in E2.
In a similar manner as was used for mapping of line 92T-32, the minimum peptide which could sensitize target cells for lysis for the HLA A23-restricted CTL line 93I-8, was the NS2 sequence YISWCLWW (aa 838-845) (Fig. 4) (Fig. 6 ). However, synthetic peptides which contain potential T cell epitopes on the basis of the amphipathicity profile of NS5B were available (reference 30, generously provided by Dr. J. Berzofsky). These peptides are partially overlapping and have been used to map an epitope recognized by murine HCV-specific CTL (25 (Table  I) , and was tested for the ability to recognize target cells incubated with peptides spanning the region overlapped by these constructs, aa 347-966 (Fig. 7) . Only the two peptides shown (aa 621-640 and 631-650) but none of the other 54 peptides which spanned the proteins of interest sensitized target cells for lysis (data not shown). The peptide TINYTIFK (aa 621-8), which lies within the E2, was able to sensitize target cells for lysis whereas loss of the amino terminal threonine or the carboxy terminal lysine abrogated recognition of target cells.
The HLA B8-restricted epitope recognized by line 94F-65 was identified using 15 (Fig. 8) . This corresponds to the (Fig. 9 B) recognized by this line showed that the peptide CINGVCWTV (aa 1073-1081) was optimal for sensitization of target cells. This conforms to the proposed motif for binding to the HLA A2. 1 molecule, with an isoleucine at position 2 and a valine at the carboxy terminus (33) . Moreover, some synthetic peptides which reflect natural variants of this epitope were not able to sensitize target cells for lysis (Fig. 9 C) , indicating that aa substitutions within this CTL epitope might affect recognition by HCV-spe- HCV-specific CTL produce multiple cytokines upon recognition oftarget cells. In murine models of viral hepatitis, cytokines produced by virus-specific CTL may serve as specific inhibitors of viral replication (reviewed in reference 15), yet may also contribute to tissue necrosis by acting as mediators of inflammation (12) . Activated macrophages and other cell types may produce large amounts of cytokines (for example, activated macrophages produce large amounts of TNF-a; reference 34), but the pattern of cytokine release by CTL is less well characterized, particularly for human CTL. The pattern of cytokine release by murine virus-specific CTL may not correspond to that of human virus-specific CTL (35) . In this study, the specific patterns of cytokine release by human HCV-specific CTL in response to recognition of target cells was investigated. For these studies, CTL which grew well and for which the minimum epitope had been precisely defined were used. In addition to the HCV-specific CTL 931-8 and 93I-58 reported here, lines 92N-47 and 92N-107, which have been previously described (4), were used for analysis of cytokine release. Line 92N-47 recognizes an epitope in HCV core, aa 41-49, (16) . Although use of B-LCL infected with the relevant HCV-recombinant vaccinia virus gave similar results when used as target cells in these assays, peptide-sensitized targets gave higher and more reproducible levels of cytokine release (data not shown).
The HCV E2-specific CTL 92N-107 produced IFN-y, TNFa, IL-8, and GM-CSF, and IL-10 only when the target cells displayed an HLA B51 molecule and were sensitized with the epitope recognized by this line, paralleling the restriction observed for the cytolytic activity of these cells (Table III) . Production of IL-4 and IL-6 could not be demonstrated for this line or any other HCV-specific CTL line (data not shown).
Similar, although not identical, patterns of cytokine release were shown with three additional lines, as shown in Table IV These HCV-specific CTL released IFN--y, TNF-a, IL-8, and GM-CSF upon recognition of the relevant peptide sensitized target cell, but did not produce IL-10. The ability to detect IL-10 after cocultivation of 92N-107 with target cells expressing B51 and sensitized with the relevant epitope was not related to levels of cytolytic activity, since other lines, such as 931-58, had a higher level of percent specific cytotoxicity and were negative for IL-10 production in the same cytokine assay. This suggests that there are different subsets of cytolytic cells, although it is possible that production of IL-10 by the other CTL was below the detection limits of the assay used.
Discussion
The role of cellular immune responses in hepatitis C virus infection is still in the early stages of characterization. In some viral infections, the response of CD8+ CTL is felt to be limited, with responses against a single protein dominating the CTL response (32, 36, 37) , especially after the acute illness has resolved and the infection has become either chronic or resolved completely (38) . However, in HIV-1 infection, which shares the property of extensive sequence heterogeneity with HCV, up to 14 different CTL epitopes have been identified within a single individual (39) . In acute HBV infection, up to five HLA A2. 1-restricted epitopes have been identified within the peripheral blood after a period of in vitro peptide stimulation (9) , although these CTL responses could not be detected in the PBMC of chronically HBV-infected individuals using the same methodology. In this report we identify multiple sites within both structural and nonstructural proteins of HCV as targets for HCVspecific CTL in chronically infected persons, without the use of exogenous in vitro antigenic stimulation. There have been other reports of HCV-specific CTL in PBMC, which were detected after prolonged periods of in vitro stimulation with synthetic peptides (40, 41) . However, at least one group has reported the induction of primary in vitro HCV-specific responses in seronegative individuals with this methodology (41, 42) , and so interpretation of the role of CTL identified following peptide stimulation awaits further study.
With nonspecific stimulation strategies, such as have been used in detecting HIV-l-specific CTL (17) as well as HCVspecific CTL (4, 5) , it is possible to detect CTL directed against multiple different antigens without influencing the specificities of the CTL in vitro. After expansion of the CD8 + liver-infiltrating lymphocytes in the liver biopsy specimen, we are able to observe responses directed against multiple proteins (in the case of 94F, five separate epitopes), restricted by a variety of HLA molecules. Since HCV displays considerable sequence hetero- (46) . The epitopes recognized by these HCV-specific CTL conform to proposed motifs, although we have also identified CTL epitopes restricted by HLA for which a peptide binding motif has not yet been proposed. For example, the HLA B7 motif is proposed to consist of a proline at position 2, arginine at position 3, and a leucine or valine at position 9 (47). The epitope recognized by the HLA B7-restricted CTL 931-58, GPRLGVRAT, is consistent with this motif, with the exception being the nonconservative substitution of a threonine at position 9. Similarly, the epitope recognized by the HLA B8-restricted CTL 94F-65 HSKKKCDEL, is consistent with the proposed motif for HLA B8, which is a lysine at position 3, lysine or arginine at position 5, and a carboxy terminal isoleucine or leucine (32) .
Since HCV is a highly heterogeneous virus and these epitopes are present within both conserved and variable regions of the genome, precise definition of the epitopes recognized by HCV-specific CTL may allow an understanding of the effect of sequence variation on the immune response to HCV. Although some aa substitutions within the middle of the CTL epitope-binding site may not affect binding of the peptide to the class I molecule (48) , other groups have shown that even single aa variations within CTL epitopes facilitates viral escape from host immunity (49, 50) . In addition to a failure of CTL to recognize variant sequences present within an epitope, several groups have recently shown that natural variants within CTL epitopes may act as antagonists to T cell receptor binding (51, 52) .
Whatever the role of HCV-specific CTL in controlling viral replication, viremia persists despite the presence of a cellular immune response in chronically infected individuals. In such circumstances, CTL may contribute to disease pathogenesis, and evidence is accumulating that cytokines may be important mediators of this immunopathology. Recent data have shown that adoptive transfer of HBV-specific CTL into HBsAgtransgenic mice led to liver cell necrosis (53) . This tissue damage is due to direct cell lysis by the CTL (35) , with amplification of liver necrosis by cytokines such as IFN-y and TNF-a (12) . The initial response appears to consist of an antigenspecific response by virus-specific CTL, followed by production of IFN-y and TNF-ca. This, in turn, leads to antigen-nonspecific recruitment of inflammatory cells, followed by activation of macrophages and a delayed-type hypersensitivity like lesion. Blockade of the cascade of events occurs when animals are pretreated with antibodies to TNF-a before adoptive transfer of HBV-specific CTL (12) . In another transgenic mouse model, liver-specific expression of IFN-y produced a transaminitis and histologic appearance similar that of human chronic active hepatitis (54).
In addition to the effects of IFN-y and TNF-a, other cytokines are produced by these human virus-specific CTL. Although the role of these cytokines has not yet been investigated in animal models, the known biologic actions of these cytokines suggest that these cytokines might also play a role in the pathogenesis of chronic hepatitis. Both GM-CSF and IL-8 lead to a recruitment of inflammatory cells (55) . IL-10 may be produced by certain classes of CD4 cells (14) , and it has been well demonstrated in murine models that two types of CD4 lymphocytes populations may be defined based on production of IFN-'y and IL-10 (56). However, production of IL-10 by virusspecific cytolytic T cells has not been reported. IL-10 is thought to be a down-regulator of immune responses (57) , and so production of this cytokine by CTL might contribute to viral persistence.
Heterogeneous production of cytokines by melanoma-specific CD8+ CTL has also been observed (58) , which may be due to different populations of CD8+ CTL or methodologic issues relating to the method of T cell stimulation. For example, it is unknown whether virus-specific CTL have a different pattern of cytokine release than tumor-specific CTL, although on the basis of these two studies this would seem unlikely. In most instances the precise targets of the cytolytic response have not been defined and production of cytokines has been measured after stimulation with immobilized anti-CD3, which has not always resulted in the same pattern of cytokine release as stimulation with the specific antigen recognized by the CTL (58) . For example, stimulation of murine CD8+ cells with an anti-CD3 antibody resulted in the production of only in Ts cells, but not in CTL (59) .
In addition, characterization of responses produced by CTL isolated from the periphery might have a different pattern of cytokine release compared to those isolated from the site of tissue damage. This tissue-specific compartmentalization of cytokine release has recently been demonstrated for CD4+ cytolytic cells isolated from the liver of patients with chronic HBV infection (60) . We have previously demonstrated the compartmentalization of HCV-specific CTL within the liver (4). To date we have not be able to isolate HCV-specific CTL within the PBMC using an antigen nonspecific stimulation strategy, and so we have not had the opportunity to compare liver-infiltrating versus PBMC-derived HCV-specific CTL for the patterns of cytokine release. However, if chronic HCV hepatitis is a T cell-mediated disease, knowledge of cytokines produced by the cells which induce the inflammatory cascade, as well as the precise targets recognized by these CTL, may suggest novel immunotherapeutic interventions.
